Synairgen (LON:SNG) Trading Down 2.9% – Time to Sell?

Synairgen plc (LON:SNG)’s stock price was down 2.9% during trading on Monday . The stock traded as low as GBX 0.80 ($0.01) and last traded at GBX 0.83 ($0.01). Approximately 160,793 shares changed hands during trading, a decline of 90% from the average daily volume of 1,578,296 shares. The stock had previously closed at GBX 0.85 ($0.01).

Synairgen Stock Down 2.9 %

The firm has a market capitalization of £8.07 million, a price-to-earnings ratio of -0.50 and a beta of -2.23. The company’s fifty day moving average is GBX 1.62 and its two-hundred day moving average is GBX 2.99.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).